MARKET

CTOR

CTOR

Citius Oncology, Inc.
NASDAQ
1.130
-0.015
-1.31%
After Hours: 1.110 -0.02 -1.77% 19:49 12/26 EST
OPEN
1.150
PREV CLOSE
1.145
HIGH
1.150
LOW
1.080
VOLUME
423.00K
TURNOVER
--
52 WEEK HIGH
6.19
52 WEEK LOW
0.5506
MARKET CAP
95.82M
P/E (TTM)
-4.0912
1D
5D
1M
3M
1Y
5Y
1D
Citius Oncology’s LYMPHIR FDA Win Clouded by High Upfront Costs, Regulatory Risks, and Uncertain Market Adoption
TipRanks · 1d ago
Citius Pharmaceuticals (CTXR) Surges 22% After Hours — Here's Why
Benzinga · 3d ago
Citius Oncology, Inc. Full Year Loss Increases
NASDAQ · 3d ago
Citius Oncology reports FY25 EPS (34c) vs. (31c) last year
TipRanks · 4d ago
Citius Oncology Q4 EPS $(0.06), Inline
Benzinga · 4d ago
Citius Oncology Subsidiary, Citius Oncology, Launches Cancer Immunotherapy, LYMPHIR, In The U.S. In December 2025 For The Treatment Of Adult Patients With Relapsed Or Refractory Stage I-III CTCL After At Least One Prior Systemic Therapy; Co. Raised ~ $61M In Gross Proceeds From Capital Raises
Benzinga · 4d ago
*Citius Oncology FY25 Loss/Shr 34c >CTOR
Dow Jones · 4d ago
Press Release: Citius Oncology, Inc. Reports -2-
Dow Jones · 4d ago
More
About CTOR
Citius Oncology, Inc. is a biopharmaceutical company. The Company is focused on developing and commercializing targeted oncology therapies. The Company’s lead product candidate is LYMPHIR, an engineered IL-2 diphtheria toxin fusion protein, for the treatment of patients with persistent or recurrent CTCL, a rare form of non-Hodgkin lymphoma. LYMPHIR is a targeted immune therapy for relapsed or refractory cutaneous T-cell lymphoma (CTCL) indicated for use in Stage I-III disease after at least one prior systemic therapy. It is a recombinant fusion protein that combines the IL-2 receptor binding domain with diphtheria toxin fragments. The agent specifically binds to IL-2 receptors on the cell surface, causing diphtheria toxin fragments that have entered cells to inhibit protein synthesis. After uptake into the cell, the diphtheria toxin (DT) fragment is cleaved and the free DT fragments inhibit protein synthesis, resulting in cell death.

Webull offers Citius Oncology Inc stock information, including NASDAQ: CTOR real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, CTOR stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading CTOR stock methods without spending real money on the virtual paper trading platform.